

1 Analyzing Data of a Multilab Replication Project with Individual Participant Data
2 Meta-Analysis: A Tutorial

3 Robbie C.M. van Aert¹

4 ¹ Department of Methodology and Statistics, Tilburg University

5 Author Note

6 I thank Marcel van Assen, Marjan Bakker, and Jelte Wicherts for their valuable
7 comments on an earlier draft of this paper.

8 Correspondence concerning this article should be addressed to Robbie C.M. van Aert,
9 P.O. Box 90153, 5000 LE Tilburg, The Netherlands. E-mail:
10 R.C.M.vanAert@tilburguniversity.edu

Abstract

11

12 Multilab replication projects such as Registered Replication Reports (RRR) and Many Labs
13 projects are used to replicate an effect in different labs. Data of these projects are usually
14 analyzed using conventional meta-analysis methods. This is certainly not the best approach,
15 because it does not make optimal use of the available data as summary rather than
16 participant data are analyzed. I propose to analyze data of multilab replication projects with
17 individual participant data (IPD) meta-analysis where the participant data are analyzed
18 directly. Prominent advantages of IPD meta-analysis are that it generally has larger
19 statistical power to detect moderator effects and allows drawing conclusions at the
20 participant and lab level. However, a disadvantage is that IPD meta-analysis is more
21 complex than conventional meta-analysis. In this tutorial, I illustrate IPD meta-analysis
22 using the RRR by McCarthy and colleagues, and I provide R code and recommendations to
23 facilitate researchers to apply these methods.

24 *Keywords:* meta-analysis, Registered Replication Report, replication, multilevel
25 analysis, individual participant data meta-analysis

26 Word count: 7611

27 Analyzing Data of a Multilab Replication Project with Individual Participant Data
28 Meta-Analysis: A Tutorial

29 Multilab replication projects are exemplary for the increased attention for replication
30 research in psychology. Prominent effects in the psychological literature are replicated in
31 these multilab replication projects in different labs across the world. These projects yield
32 highly relevant insights about whether an effect can actually be replicated and also whether
33 the effect depends on contextual factors such as the location where a study was conducted.
34 Multiple registered replication reports (RRRs, Simons, Holcombe, & Spellman, 2014) have
35 been conducted where a single effect is replicated in different labs as well as Many Labs
36 projects (Ebersole et al., 2016, 2020; Klein et al., 2021, 2014, 2018) where multiple effects are
37 replicated in a large collaborative project.

38 The main publication outlet for multilab replication projects within psychology was the
39 journal *Perspectives on Psychological Science*, but *Advances in Methods and Practices in*
40 *Psychological Science* has taken over this role since its launch in 2018. Twelve RRRs were
41 published in these journals since the introduction of RRRs and until September 6, 2021.
42 Moreover, the Many Labs projects replicated 12, 28, 10, 1, and 10 effects in Many Labs 1, 2,
43 3, 4, and 5, respectively. These published RRRs and Many Labs projects show that multilab
44 replication projects are not uncommon, and these projects are expected to become more
45 popular due to the increased attention for replications and the desire to study the credibility
46 of psychological science.

47 The usual analysis strategy for analyzing the data of a single effect in multilab
48 replication projects is equivalent to how a conventional meta-analysis is conducted. That is,
49 a summary effect size (e.g., [standardized] mean difference or correlation) and corresponding
50 sampling variance (i.e., squared standard error) is computed for each lab and these summary
51 effect sizes are then usually synthesized by means of a random-effects meta-analysis. The
52 meta-analytic average effect size is of interest as well as whether the true effect size of the

53 labs are heterogeneous and whether this heterogeneity can be explained by moderator
54 variables in a so-called meta-regression model (e.g., Thompson & Sharp, 1999; Van
55 Houwelingen, Arends, & Stijnen, 2002). This is a valid but certainly also suboptimal
56 approach, because the differences of participants within a lab are lost by aggregating the
57 data to summary effect sizes. I propose to analyze data of multilab replication projects by
58 means of an individual participant data (IPD) meta-analysis where the participant data are
59 analyzed rather than summary effect sizes (e.g., L. A. Stewart & Tierney, 2002). Multilab
60 replication projects are ideal for applying IPD meta-analysis as the participants' data is, in
61 contrast to traditional studies, readily available.

62 IPD meta-analysis is popular among medical researchers, and it is commonly referred
63 to as individual *patient* data meta-analysis. In contrast to research in psychology, medical
64 research has a longer history with respect to sharing data that enables researchers to conduct
65 IPD meta-analysis. For example, the prominent medical journal BMJ required authors to
66 agree on sharing the IPD data of clinical trials of drugs or devices on request in 2013, and
67 this policy was extended to all trials in 2015 (Godlee, 2012; Loder & Groves, 2015). Medical
68 research also frequently uses binary data (e.g., dead vs. alive and treatment vs. placebo
69 group), and these data can easily be reported in a 2x2 frequency table making reporting of
70 IPD data less cumbersome compared to fields like psychology that mainly use continuous
71 data. These developments together with the call for more personalized treatments
72 (Hingorani et al., 2013) made that IPD meta-analysis is nowadays seen as the gold standard
73 for synthesizing studies in medical research (Riley et al., 2008; Rogozińska, Marlin,
74 Thangaratinam, Khan, & Zamora, 2017; Simmonds et al., 2005).

75 IPD meta-analysis has many advantages over conventional meta-analysis (Riley,
76 Lambert, & Abo-Zaid, 2010; L. A. Stewart & Tierney, 2002). Two advantages are especially
77 valuable for analyzing data of multilab replication projects. First, participant level
78 moderators can be included to explain heterogeneity in true effect size, which is one of the

79 main aims in multilab replication projects. Heterogeneity in conventional meta-analysis can
80 only be attributed to study level characteristics and not to characteristics of the participants
81 within a lab, because summary statistics of the primary studies are analyzed rather than the
82 underlying participant data. Researchers who draw conclusions at the participant level using
83 summary effect sizes may introduce aggregation bias and commit an ecological fallacy (e.g.,
84 Berlin, Santanna, Schmid, Szczech, & Feldman, 2002; Borenstein, Hedges, Higgins, &
85 Rothstein, 2009), which will be illustrated below. Second, statistical power to test
86 moderating effects is usually larger than of conventional meta-regression. Simmonds and
87 Higgins (2007) analytically showed that statistical power of testing a moderator variable in
88 IPD meta-analysis is always larger than of conventional meta-regression in a fixed-effect
89 meta-analysis (a.k.a. equal-effect) model. The only exception is when all participant scores
90 on the moderator variable within primary studies are the same, because statistical power of
91 conventional meta-regression and IPD meta-analysis is equivalent in this situation. Lambert,
92 Sutton, Abrams, and Jones (2002) compared statistical power of IPD meta-analysis with
93 conventional meta-regression in a fixed-effect meta-analysis model using simulations and
94 showed that statistical power of IPD meta-analysis was especially larger when the effect size,
95 number of primary studies, and sample size in the primary studies was small.

96 The goal of this paper is to illustrate how data of a multilab replication project can be
97 analyzed by means of an IPD meta-analysis. The focus of this paper will be on estimation of
98 the average effect size as well as on quantifying the heterogeneity in true effect size and
99 explaining this heterogeneity with moderator variables, because both aspects are generally
100 studied in multilab replication projects (e.g., Ebersole et al., 2016; Klein et al., 2014, 2018).
101 Two different approaches to IPD meta-analysis are a one-stage and two-stage approach that
102 I will both explain and illustrate. Before turning to IPD meta-analysis, I will first provide an
103 example of aggregation bias in a meta-regression model. Subsequently, I will introduce the
104 RRR by McCarthy et al. (2018) that will be used for illustrating the methods and explain
105 how these data are commonly analyzed using conventional random-effects meta-analysis.

106 The paper ends with a conclusion section that contains recommendations for analyzing data
107 of a multilab replication project.

108 **Illustration of aggregation bias in meta-regression**

109 Aggregation bias or an ecological fallacy refers to a situation where conclusions are
110 drawn for individuals based on aggregated data (Robinson, 1950). Meta-analysts can easily
111 fall into the trap of introducing aggregation bias if they do not realize that differences
112 between labs in a meta-regression analysis can only be attributed to lab level characteristics
113 (e.g., Berlin, Santanna, Schmid, Szczech, & Feldman, 2002; Borenstein, Hedges, Higgins, &
114 Rothstein, 2009). Figure 1A shows data of three labs using a two-independent groups design
115 where scores of participants in the experimental and control group are denoted by E and C,
116 respectively. The main interest in this analysis is to study whether age has a moderating
117 effect on the grouping variable, so whether the effect of the manipulation is strengthened (or
118 weakened) by participant's age.

119 The model underlying the data of all three labs is a linear regression model. That is,
120 for lab 1 $51 - 18x + x \times age$, for lab 2 $46 - 30x + x \times age$, and for lab 3 $41 - 42x + x \times age$
121 where x denotes whether a participant belongs to the experimental ($x = 1$) or control ($x = 0$)
122 group and age is the participant's age. Within each lab, the age of participants in the
123 experimental group is larger than of the participants in the control group. This may occur in
124 practice if participants are not randomly assigned to one of the two groups. The regression
125 equations show that the only differences between the labs are the intercept and the effect of
126 the manipulation. These data indicate that there is a positive interaction effect between the
127 grouping variable and age at the participant level, so the effect of the manipulation is
128 strengthened by participant's age.

129 Table 1 shows the summary statistics that are used as input for the meta-regression
130 analysis. The focus in the meta-regression analysis is on the relationship between the raw




Figure 1. Artificial example to illustrate aggregation bias in the context of meta-regression analysis. Figure 1A shows the individual participant data and Figure 1B shows the data analyzed in the meta-regression analysis.

131 *mean* difference of the experimental and control group and the lab’s *mean* age. This implies
 132 that we are no longer allowed to draw conclusions at the participant level as we are analyzing
 133 summary statistics of the labs. Figure 1B shows the raw mean difference and mean age per
 134 lab. The relationship between the raw mean difference and mean age is negative (dashed line
 135 in Figure 1B) and contradicts the finding of the analysis based on the participant data.

136 This example illustrates that the interaction effect may be substantially different at the
 137 lab compared to the participant level. The effect at a higher level can be in the opposite
 138 direction compared to the lower level (Aitkin & Longford, 1986; Snijders & Bosker, 1999).
 139 Although this example was created in a way to illustrate aggregation bias, it may also occur

Table 1

Sample means of the dependent variable in the experimental (Exp.) and control group and the moderator age. Raw mean diff. is the raw mean difference of the sample means in the experimental and control group.

| | Sample means | | | |
|-------|--------------|---------|------|----------------|
| | Exp. | Control | Age | Raw mean diff. |
| Lab 1 | 57 | 51 | 22.5 | 6 |
| Lab 2 | 50 | 46 | 32.5 | 4 |
| Lab 3 | 43 | 41 | 42.5 | 2 |

140 in practice and can only be studied if participant data are available. Hence, this example
 141 also shows that a meta-regression cannot be used to draw conclusions at the participant level
 142 as it is prone to committing an ecological fallacy. A meta-regression is, however, suitable to
 143 draw conclusions about moderating effects measured at the level of the lab. This implies
 144 that the results of the meta-regression in this example can be used to draw conclusions
 145 about the lab's mean age on the raw mean difference.

146 **Example of a Registered Replication Report**

147 The RRR by McCarthy et al. (2018) replicated the study by Srull and Wyer (1979) on
 148 assimilative priming. Assimilative priming refers to the idea that “exposure to priming
 149 stimuli causes subsequent judgments to incorporate more of the qualities of the primed
 150 construct” (McCarthy et al., 2018, p. 322). In the replicated experiment, participants were
 151 first asked to perform a sentence construction task where either 20% or 80% of the sentences
 152 described hostile behavior. Participants were then asked to read a vignette about a man
 153 called Donald who behaved in an ambiguously hostile way and rated Donald's behavior on
 154 12 traits to get a score of the extent he was perceived as hostile. All 12 traits were measured
 155 on a scale ranging from 0 (not at all) to 10 (extremely) and six of these traits were averaged

156 to create a hostility rating. The tested hypothesis was that participants who were exposed to
157 a larger number of sentences describing hostile behavior would rate Donald's behavior as
158 more hostile.

159 The RRR by McCarthy et al. (2018) was selected for illustrating the different
160 meta-analysis models, because the data are well-documented, it was possible to reproduce
161 the reported results, variables were reported that could be included in the models as
162 moderator, and a two-independent groups design was used, which is common in psychology.
163 The effect size measure of interest was, as by McCarthy et al. (2018), the raw mean
164 difference. The raw mean difference is a common effect size measure in multilab replication
165 projects, because the dependent variable is measured in the same way in each lab. Hence,
166 computing standardized mean differences is not necessary and even undesired if the data can
167 be analyzed on its original (unstandardized) scale (e.g., Baguley, 2009; Bond Jr., Wiitala, &
168 Richard, 2003; Wilkinson, 1999). The study was replicated in 22 labs and the total sample
169 size was 7,373 (see McCarthy et al., 2018 for more details). All analyses were conducted in
170 the statistical software R (Version 4.1.0, R Core Team, 2021), the R package `papaja` (Aust
171 & Barth, 2020) was used for writing the paper, and annotated R code to analyze the RRR is
172 available in the supplemental materials at <https://osf.io/c9zep/>.

173

Random-effects model

174 The conventional random-effects model is usually fitted to data of multilab replication
175 projects, and this is also how the data of the RRR by McCarthy et al. (2018) were analyzed.
176 A requirement for applying the random-effects model is that summary effect sizes and
177 corresponding sampling variances per lab are computed. Formulas for computing these
178 summary effect sizes and sampling variances are available in Borenstein and Hedges (2019). I
179 will continue with describing the random-effects model before applying this model to the
180 RRR.

181 **Statistical model**

182 The random-effects model assumes that the effect size y_i is observed for each i th lab.
183 The statistical model can be written as (e.g., Borenstein, Hedges, Higgins, & Rothstein, 2009)

$$y_i = \mu + \mu_i + \epsilon_i, \quad (1)$$

184 where μ is the average true effect size, μ_i is the random effect denoting the difference between
185 the average true effect size μ and a lab's true effect size θ_i , and ϵ_i reflects the sampling error.
186 The random effect μ_i is commonly assumed to follow a normal distribution with mean zero
187 and variance τ^2 , and the sampling error ϵ_i is assumed to follow a normal distribution with
188 mean zero and variance σ_i^2 . The μ_i and ϵ_i are assumed to be mutually independent of each
189 other, and it is common practice to estimate σ_i^2 and then assume that its value is known.

190 The most interesting outcomes in a multilab replication project are the parameters μ
191 and τ^2 . The parameter μ denotes the meta-analytic average effect size estimate yielding
192 insight into the true effect size of the replicated study and can also be used to assess whether
193 the original study can be deemed to be successfully replicated. The parameter τ^2 reflects the
194 between-study variance in true effect size and indicates whether the lab's true effect sizes θ_i
195 are all the same (homogeneous) or different from each other (heterogeneous). Heterogeneity
196 in true effect size can be explained by extending the statistical model in (1) to a
197 random-effects meta-regression model where study characteristics are included as moderators
198 (e.g., Thompson & Sharp, 1999; Van Houwelingen, Arends, & Stijnen, 2002). That is, a lab's
199 true effect size becomes a regression equation in a random-effects meta-regression model
200 (e.g., $\beta_0 + \beta_1 x$ where x is a moderator variable).

201 **Fitting the random-effects model to the data**

202 Before fitting the random-effects model to the RRR, I first computed the raw mean
203 differences and corresponding sampling variances for each lab (see supplemental materials at
204 <https://osf.io/c9zep/>). I used the R package `metafor` (Version 3.0.2, Viechtbauer, 2010) for

205 fitting the random-effects model. The random-effects model can be fitted using the `rma()`
 206 function of the `metafor` package by providing the lab's raw mean differences (argument `yi`)
 207 and the corresponding sampling variances (argument `vi`). R code for fitting the
 208 random-effects model is¹

```
209     rma(yi = yi, vi = vi, data = ma_dat)
```

210 where `ma_dat` is a data frame containing the `yi` and `vi`.

Table 2

Results of fitting a random-effects model (RE MA) and two-stage and one-stage individual participant data meta-analysis to the registered replication report by McCarthy et al. (2018).

| | $\hat{\mu}$ (SE) | (95% CI) | Test $H_0: \mu = 0$ | $\hat{\tau}^2$ | (95% CI) | Test $H_0: \tau^2 = 0$ |
|-----------|------------------|---------------|--------------------------|----------------|-----------|------------------------------|
| RE MA | 0.083 (0.040) | (0.004;0.161) | $z=2.058, p=0.040$ | 0.006 | (0;0.043) | $Q(21)=25.313, p=0.234$ |
| Two-stage | 0.082 (0.040) | (0.004;0.161) | $z=2.055, p=0.040$ | 0.006 | (0;0.043) | $Q(21)=25.266, p=0.236$ |
| One-stage | 0.090 (0.038) | (0.017;0.164) | $t(18.6)=2.356, p=0.030$ | 0.002 | (0;0.012) | $\chi^2(2)=0.554, p=0.758^a$ |

Note: $\hat{\mu}$ is the estimate of the average true effect size, SE refers to standard error, CI refers to confidence interval, and $\hat{\tau}^2$ is the estimate of the between-study variance obtained with restricted maximum likelihood estimation. ^a the `anova()` function conducts the likelihood-ratio test by first fitting the models to be compared with full maximum likelihood estimation.

211 The results of fitting the random-effects model are presented in the first row of Table 2.
 212 These results exactly match those of Figure 1 in McCarthy et al. (2018). The average true
 213 effect size estimate is equal to $\hat{\mu} = 0.083$ (95% confidence interval (CI) [0.004;0.161]), and the
 214 null-hypothesis of no effect was rejected ($z = 2.058$, two-tailed p -value = 0.040). These
 215 results imply that the average raw mean difference between the mean hostility rating of
 216 participants in the 80%-hostile priming condition and those in the 20%-hostile priming
 217 condition was 0.083. Hence, the mean hostility rating of participants in the 80%-hostile

¹ The restricted maximum likelihood estimator (Raudenbush, 2009) was used for estimating the between-study variance τ^2 . This is the default estimator of `metafor` and also allows direct comparison with the results of IPD meta-analysis as these also rely on restricted maximum likelihood estimation.

218 priming conditions was larger than those in the 20%-hostile priming condition. There was a
 219 small amount of heterogeneity observed in the true effect sizes. The estimate of the
 220 between-study variance $\hat{\tau}^2 = 0.006$ (95% CI [0;0.043])², Cochran's Q -test (Cochran, 1954) for
 221 testing the null-hypothesis of no between-study variance was not statistically significant
 222 ($Q(21) = 25.313$, p -value = 0.234).

223 The null-hypothesis of no heterogeneity could not be rejected, which is common for
 224 multilab replication projects that consist of direct replications (Olsson-Collentine, Wicherts,
 225 & Van Assen, 2020). However, the estimated small between-study variance suggested that a
 226 small amount of heterogeneity in the true effect size was present in the meta-analysis. This
 227 heterogeneity can be explained by including moderators measured at the lab level in a
 228 random-effects meta-regression analysis. The moderator variable mean age of participants
 229 per lab is included in this paper for illustrating the methods, but the procedure is similar for
 230 any moderator variable. After computing this mean age per lab, the random-effects
 231 meta-regression model can be fitted to the data using the following code

```
232 rma(yi = yi, vi = vi, mods = ~ m_age, data = ma_dat)
```

233 where `mods = ~ m_age` indicates that mean age of participants per lab is included as
 234 moderator.

235 The results of fitting the random-effects meta-regression model are shown in the first
 236 two rows of Table 3.³ The coefficient of the variable mean age is 0.050 ($z = 1.237$, two-tailed

² The 95% CI for the between-study variance τ^2 is not in the output of fitting the random-effects model. Such a CI can, for instance, be obtained using the Q -profile method (Viechtbauer, 2007) via the function `confint()` where the only argument of the function is the object obtained by running the function `rma()`. See the supplemental materials for the actual code and output (<https://osf.io/c9zep/>).

³ The intercept of this random-effects meta-regression model refers to the average true effect size estimate conditional on a mean age of zero. If the intercept is of interest to the meta-analyst, it is advised to center the variable mean age at, for instance, the grand mean (i.e., the overall mean of age) to increase the

237 p -value = 0.216, 95% CI [-0.029;0.128]) implying that a one unit increase in *mean* age leads
238 to a predicted increase of 0.050 in the average raw mean difference. The estimate of the
239 residual between-study variance was $\hat{\tau}^2 = 0.005$ (95% CI [0;0.043], $Q(20) = 23.456$, p -value =
240 0.267). These results of fitting the random-effects model and random-effects meta-regression
241 model will be contrasted with the results of IPD meta-analysis when describing those results.

interpretability. The intercept can then be interpreted as the average true effect size estimate conditional on a mean age equal to the grand mean of age.

Table 3

Results of fitting a random-effects meta-regression model (RE MR) and two-stage and one-stage individual participant data meta-analysis where age is included as a moderator variable to data of the registered replication report by McCarthy et al. (2018).

| | Estimate (SE) | (95% CI) | Test of no effect | $\hat{\tau}^2$ | (95% CI) | Test $H_0: \tau^2 = 0$ |
|-------------|----------------|-----------------|----------------------------|----------------|-----------|------------------------------|
| RE MR | | | | | | |
| Intercept | -0.921 (0.812) | (-2.512;0.671) | $z=-1.134, p=0.257$ | 0.005 | (0;0.043) | $Q(20)=23.456, p=0.267$ |
| Mean age | 0.050 (0.040) | (-0.029;0.128) | $z=1.237, p=0.216$ | | | |
| Two-stage | | | | | | |
| Age | 0.053 (0.024) | (0.007;0.100) | $z=2.238, p=0.025$ | 0 | (0;0.011) | $Q(21)=18.006, p=0.649$ |
| One-stage | | | | | | |
| Intercept | 8.264 (0.353) | (7.570;8.951) | $t(1701.0)=23.420, p<.001$ | | | |
| x | -0.791 (0.814) | (-2.308;0.820) | $t(18.8)=-0.972, p=0.343$ | | | |
| Age | -0.064 (0.017) | (-0.096;-0.030) | $t(4477.1)=-3.780, p<.001$ | 0.003 | (0;0.011) | $\chi^2(2)=0.355, p=0.837^a$ |
| Age within | 0.050 (0.024) | (0.003;0.096) | $t(5331.4)=2.074, p=0.038$ | | | |
| Age between | 0.044 (0.040) | (-0.036;0.118) | $t(18.8)=1.087, p=0.291$ | | | |

Note: SE refers to standard error, CI refers to confidence interval, and $\hat{\tau}^2$ is the estimate of the between-study variance obtained with restricted maximum likelihood estimation. “x” is a dummy variable that determines whether a participant is in the control (=reference category) or experimental group, “Age within” is the within-lab interaction between age and “x,” and “Age between” is the between-lab interaction between age and “x.” ^a the anova() function conducts the likelihood-ratio test by first fitting the models to be compared with full maximum likelihood estimation.

Individual participant data meta-analysis

242

243 Meta-analysis models can be seen as a special case of multilevel models (also known as
244 mixed-effects models) with at level 1 the participants within studies and at level 2 the
245 studies. This is also the reason why meta-analysis models are discussed in books on
246 multilevel models (e.g., Hox, Moerbeek, & Van de Schoot, 2018). This equivalence between
247 meta-analysis and multilevel models becomes even more apparent when we move from the
248 conventional random-effects model analyzing summary effect sizes to IPD meta-analysis
249 analyzing the participants' data directly, because IPD meta-analysis models are actually
250 multilevel models applied to participants who are nested in studies.

251

252 Two different approaches to IPD meta-analysis are common: the one-stage and
253 two-stage approach. In the two-stage approach, effect sizes are first computed for each lab
254 and these are subsequently meta-analyzed. The one-stage approach does not require the
255 computation of effect sizes per lab, because the data are modeled directly using a multilevel
256 model. Both approaches allow drawing inferences regarding moderator variables at the
257 participant level in contrast to the meta-regression model. Moreover, both approaches
258 generally yield similar (average) effect size estimates (e.g., Koopman, Van der Heijden, Hoes,
259 Grobbee, & Rovers, 2008; G. B. Stewart et al., 2012; Tierney, Fisher, Burdett, Stewart, &
260 Parmar, 2020; Tudur Smith & Williamson, 2007), but larger practically relevant differences
261 can also be observed (Tudur Smith et al., 2016).

261

262 The two-stage approach is appealing to researchers familiar with conventional
263 meta-analysis models due to the close similarities between the two. Actually, one of the
264 conventional meta-analysis models (i.e., the fixed-effect or random-effects model) is fitted in
265 the second step of the two-stage approach. However, the differences between the
266 conventional and two-stage IPD meta-analysis model also offers opportunities to gain better
267 insights. Additional variables can be included in the first step of the two-stage approach to
268 control for these variables, which is impossible in the conventional meta-analysis model. The

268 most important difference is that analyzing the participant data in the first step of the
 269 two-step approach allows to draw inferences at the *participant* level. The conventional
 270 meta-analysis model uses summary statistics per lab for studying the effect of moderators
 271 and therefore only allows for drawing inferences at the *lab* level.

272 Despite these appealing properties of two-stage IPD meta-analysis, there are reasons
 273 for applying a one-stage rather than a two-stage IPD meta-analysis approach. For example,
 274 the two-stage approach has lower statistical power except for situations where all labs have
 275 the same mean on the moderator variable (Fisher, Copas, Tierney, & Parmar, 2011;
 276 Simmonds & Higgins, 2007). Furthermore, the one-stage approach is also more flexible and
 277 does not require the assumption of known sampling variances σ_i^2 (Papadimitropoulou,
 278 Stijnen, Dekkers, & Cessie, 2019). This approach is, however, also more complicated to
 279 implement as convergence problems may arise in the one-stage approach whereas these are
 280 less common in the two-stage approach (Kontopantelis, 2018).

281 I generally recommend applying one-stage IPD meta-analysis, but the two-stage
 282 approach is a useful “stepping stone” to move from the random-effects meta-analysis model
 283 to one-stage IPD meta-analysis. Hence, I continue with describing two-stage IPD
 284 meta-analysis before illustrating one-stage IPD meta-analysis.

285 **Statistical model two-stage approach**

286 The first step of the two-stage approach consists of fitting a linear regression model to
 287 the participant data of each *i*th lab. In case of raw mean differences, the linear regression
 288 model is (e.g., Riley et al., 2008)

$$y_{ij} = \phi_i + \theta_i x_{ij} + \epsilon_{ij} \quad (2)$$

289 where y_{ij} denotes the score on the dependent variable of participant *j* in lab *i*, ϕ_i is a fixed
 290 lab effect, x_{ij} is a dummy variable indicating whether participant *j* in lab *i* belongs to the
 291 experimental or control group, and ϵ_{ij} is the sampling error of participant *j* in lab *i*. The

292 same assumptions as for the random-effects model apply, so $\theta_i \sim N(\mu, \tau^2)$, $\epsilon_{ij} \sim N(0, \sigma_i^2)$,
 293 and θ_i and ϵ_i are assumed to be mutually independent. There is no heterogeneity between
 294 labs if all θ_i are equal, and the parameters μ and τ^2 are again the main parameters of
 295 interest as these indicate the average treatment effect and the between-study variance in true
 296 effect size.

297 The linear regression model in (2) is fitted to the data of each i th lab in order to get
 298 an estimate of the raw mean difference ($\hat{\theta}_i$) and corresponding sampling variance. In the
 299 second step of the two-stage approach, these mean differences $\hat{\theta}_i$ are combined using the
 300 random-effects model in statistical model (1). That is, a conventional random-effects model
 301 is fitted using as input $\hat{\theta}_i$ as effect size estimate and $Var[\hat{\theta}_i]$ as sampling variance for each
 302 study.

303 The effect of moderator variables in a two-stage IPD meta-analysis is studied by
 304 adding interactions between the moderators and the grouping variable x_{ij} to the linear
 305 regression model described in (2). In case of one moderator variable, the linear regression
 306 model fitted to the data of each i th lab is (e.g., Riley et al., 2008)

$$y_{ij} = \phi_i + \alpha_i w_{ij} + \theta_i x_{ij} + \gamma_i w_{ij} x_{ij} + \epsilon_{ij} \quad (3)$$

307 where α_i is the predicted change in the dependent variable for participants in the control
 308 group if the moderator variable w_{ij} increases with one unit and γ_i denotes the interaction
 309 effect of moderator w_{ij} with the grouping variable x_{ij} . Inclusion of the main effect of the
 310 moderator variable is especially beneficial if participants were not randomly assigned to
 311 either the experimental and control group, because it controls for differences between these
 312 groups.

313 Estimates of γ_i and the corresponding sampling variances have to be stored for each
 314 i th lab if moderator effects are studied in the two-stage approach. The second step when
 315 estimating moderator effects is equivalent to the second step when estimating the average

316 true effect except that now the random-effects model in (1) is fitted to the γ_i . This two-stage
317 approach is also called a “meta-analysis of interactions” since moderator effects are now
318 meta-analyzed (Simmonds & Higgins, 2007).

319 **Applying the two-stage approach to the data**

320 A linear regression model can be fitted to the participant data of each i th lab by using
321 the function `lm()` in the preloaded R package `stats` (R Core Team, 2021). The `lm()`
322 function requires as argument the regression equation in so-called formula notation. The
323 linear regression model in (2) can be fitted using the code

```
324 lm(y ~ x)
```

325 where `y ~ x` denotes that a linear regression model is fitted with dependent variable `y` and
326 independent variable `x`. The variables `y` and `x` refer to y_{ij} and x_{ij} of the i th lab in linear
327 regression model (2). This R code has to be executed per lab and the regression coefficient of
328 variable x_{ij} and its sampling variance has to be stored for each lab. The supplemental
329 materials provide code for extracting this information from the output in R
330 (<https://osf.io/c9zep/>).

331 R code of the second step is highly similar to the code for fitting the random-effects
332 model,

```
333 rma(yi = thetai_hat, vi = vi_thetai_hat, data = ma_dat)
```

334 where `thetai_hat` is the regression coefficient of variable x_{ij} and `vi_thetai_hat` is the
335 corresponding sampling variance.

336 The results of the two-stage IPD meta-analysis are presented in the second row of
337 Table 2. These results were highly similar to the ones of the random-effects model fitted to
338 the summary effect sizes. The average true effect size estimate slightly decreased ($\hat{\mu} = 0.082$,

339 95% CI [0.004;0.161]), but was still statistically significant ($z = 2.055$, two-tailed p -value =
 340 0.040). The estimate of the between-study variance remained the same ($\hat{\tau}^2 = 0.006$, 95% CI
 341 [0;0.043]) and was not statistically significant ($Q(21) = 25.266$ with p -value = 0.236).

342 The linear regression model in (3) has to be fitted in the first step of a two-stage IPD
 343 meta-analysis in order to study whether age has a moderating effect on the dependent
 344 variable. This can be done by using the `lm()` function,

```
345 lm(y ~ x + age + x:age)
```

346 where `age` is the age of participant j in lab i and `x:age` denotes the interaction effect
 347 between the grouping variable and the moderating variable age. After storing the estimated
 348 coefficient of the interaction effect and its sampling variance, the random-effects model can
 349 be fitted analogous to how we fitted this model for the two-stage IPD meta-analysis for the
 350 lab's estimated treatment effect $\hat{\theta}_i$,

```
351 rma(yi = gammai, vi = vi_gammai, data = ma_dat)
```

352 where `gammai` and `vi_gammai` are the estimated coefficient of the interaction effect and
 353 corresponding sampling variance, respectively.

354 The results of the two-stage IPD meta-analysis are presented in the third row of Table
 355 3. The coefficient of the variable age was slightly larger than the coefficient of the variable
 356 mean age obtained with the random-effects meta-regression model (0.050 vs. 0.053), which
 357 suggested that the effects at the participant and lab level were comparable. The variable age
 358 was statistically significant in the two-stage IPD meta-analysis ($z = 2.238$, two-tailed p -value
 359 = 0.025). This indicates that the effect of assimilative priming on the hostility rating was
 360 moderated by age. The between-study variance of the true effects of the interaction was
 361 estimated as $\hat{\tau}^2 = 0$, and the null-hypothesis of no heterogeneity was not rejected
 362 ($Q(21) = 18.006$ with p -value = 0.649).

363 **Statistical model one-stage approach**

364 The linear regression model in (2) is fitted in a single analysis using a multilevel model
 365 in one-stage IPD meta-analysis. A controversial modeling decision is whether the effects of
 366 the labs (parameter ϕ_i in linear regression model (2)) have to be treated as fixed or random
 367 effects (Brown & Prescott, 2015; Higgins, Whitehead, Turner, Omar, & Thompson, 2001).
 368 Fixed effects imply that separate intercepts are estimated for each lab, so the number of
 369 parameters increases if the number of labs increase. This makes the model not parsimonious
 370 and its results can be difficult to interpret. Treating the effects as fixed implies that
 371 inferences can only be drawn for the included effects. Treating the effects as random implies
 372 the assumption that the effects are a random sample from a population of effects. Random
 373 effects allow, in contrast to fixed effects, researchers to generalize the results to the
 374 population effects. This is the reason why including the lab's effects as random effects has
 375 been argued as more appropriate than fixed lab's effects (Schmid, Stark, Berlin, Landais, &
 376 Lau, 2004). However, estimation of the variance of the population of effects may be difficult
 377 in case of a small number of labs (Brown & Prescott, 2015), so random effects may still be
 378 incorporated as fixed parameters in the model to avoid imprecise estimation of this variance.
 379 Another solution is to fit this model in a Bayesian framework where prior information about
 380 the variance of the population effects can be incorporated (e.g., Chung, Rabe-Hesketh, Dorie,
 381 Gelman, & Liu, 2013)

382 The linear regression model in (3) can be fitted in a single analysis to include
 383 moderator variables in a one-stage IPD meta-analysis approach. However, the within and
 384 between-lab interaction between the grouping and moderating variable are not disentangled
 385 by fitting this model. A better approach that disentangles the within and between lab
 386 interaction is to fit the linear regression model (Riley et al., 2008)

$$y_{ij} = \phi_i + \alpha_i w_{ij} + \theta_i x_{ij} + \gamma_W x_{ij}(w_{ij} - m_i) + \gamma_B x_{ij} m_i + \epsilon_{ij} \quad (4)$$

387 where m_i is the mean of the moderator of the i th lab and γ_W and γ_B is the within and

388 between-lab interaction between the moderating and grouping variable. The term
389 $\gamma_W x_{ij}(w_{ij} - m_i)$ is the interaction effect of the grouping variable and the moderator variable
390 minus the i th lab's mean of the moderating variable. This is known as group-mean centering
391 in the literature on multilevel modeling (e.g., Enders & Tofghi, 2007). Also including the
392 interaction between the grouping variable and the lab mean in the model (i.e., $\gamma_B x_{ij} m_i$)
393 allows for disentangling the within and between-lab interaction of the grouping and
394 moderator variable.

395 **Applying the one-stage approach to the data**

396 The one-stage IPD meta-analysis model can be fitted to the data by using the R
397 package `lme4` (Version 1.1.27.1, Bates, Mächler, Bolker, & Walker, 2015) and the R package
398 `lmerTest` (Version 3.1.3, Kuznetsova, Brockhoff, & Christensen, 2017) has to be loaded to
399 get p -values for hypothesis tests of fixed effects.⁴ I show how to fit the one-stage IPD
400 meta-analysis model with random effects for lab's effects in the paper, but R code for fitting
401 the model with fixed effects as lab's effects is available in the supplemental material at
402 <https://osf.io/c9zep/>.⁵

⁴ There is debate about whether p -values should be reported in the context of multilevel models, because it is currently unknown how the denominator degrees of freedom should be computed. I decided to explain how to obtain p -values and report those for the one-stage IPD meta-analysis as researchers have a strong desire to interpret and report p -values. However, it is important to realize that these p -values are based on approximated rather than exact denominator degrees of freedom. Luke (2017) showed by means of simulations that the default Satterthwaite approximation implemented in the R package `lmerTest` (Kuznetsova, Brockhoff, & Christensen, 2017) adequately controlled Type-I error and had comparable statistical power to other methods.

⁵ I conducted a small Monte-Carlo simulation study to examine whether the estimate of the treatment effect, its standard error, and the estimate of the between-study variance were different for models with random and fixed effects as lab's effects. Data were generated using a procedure to stay as close as possible to the data of the RRR by McCarthy et al. (2018). That is, parameter estimates of the one-stage IPD meta-analysis with random effects for lab's effects were used for generating data and the same number of labs as in the RRR was

403 The statistical model in (2) can be fitted with random lab effects using the R code

```
404 lmer(y ~ x + (x | lab), data = ipd_dat)
```

405 where `ipd_dat` is a data frame containing the variables that are included in this model.

406 Random effects are specified in the `lmer()` function by including terms between brackets.

407 Here `(x | lab)` indicates that a model is fitted with a random intercept for lab and a

408 random slope for the treatment effect that are allowed to be correlated.

409 The results of fitting one-stage IPD meta-analysis to the data are shown in the last row

410 of Table 2. The results are similar to the ones obtained with the random-effects model and

411 two-stage IPD meta-analysis. The average effect size estimate is $\hat{\mu} = 0.090$ (95% CI [0.017;

412 0.164]), and this effect size is significantly different from zero ($t(18.6) = 2.356$, two-tailed

413 p -value = 0.030). The estimate of the between-study variance was close to zero ($\hat{\tau}^2 = 0.002$)

414 and not statistically significant ($\chi^2(2) = 0.554$, p -value = 0.758). The correlation between

415 the intercepts and slopes of the labs was equal to 0.591, so labs with a larger hostility rating

416 in the control group also showed a larger effect of assimilative priming.

417 The statistical model in (4) to study the interaction effect between age and the

418 grouping variable can also be fitted with the `lmer()` function. The following R code fits the

419 model

```
420 lmer(y ~ x + (x | lab) + age + I(age-age_gm):x + age_gm:x, data =
```

```
421 ipd_dat)
```

422 where `I(age-age_gm):x` is the interaction effect between the grouping variable and the

used. Sample sizes were based on the observed sample sizes in the labs, but these were also systematically varied as small sample sizes were expected to be favorable for fixed effects as lab's effects. Results were highly similar for the two different one-stage IPD meta-analysis models. Non-convergence occurred in approximately 50% of the iterations. For more details about this Monte-Carlo simulation study, R code, and all results see <https://osf.io/r5kqy/>.

423 group-mean centered age variable and `age_gm:x` is the interaction effect between the mean
424 age per lab and the grouping variable.

425 The results of one-stage IPD meta-analysis with age as moderating variable are
426 included in the last rows of Table 3. Estimates of the intercept and the “x” are controlled for
427 other variables in the model and reflect the estimated average score of participants in the
428 control group and the estimated treatment effect. Estimates of the variables “Age within”
429 and “Age between” are of particular interest as these indicate the interaction effect between
430 the grouping variable and age within and between labs. There was a small positive
431 interaction effect within labs $\hat{\gamma}_W = 0.050$ (95% CI [0.003; 0.096], $t(5331.4) = 2.074$,
432 two-tailed p -value = 0.038), but not between labs $\hat{\gamma}_B = 0.044$ (95% CI [-0.036; 0.118], $t(18.8)$
433 = 1.087, two-tailed p -value = 0.291). However, $\hat{\gamma}_W$ and $\hat{\gamma}_B$ were highly comparable, so there
434 were no clear indications that the interaction effect was different between and within labs.
435 Also note the difference in degrees of freedom for testing these interaction effects that may
436 caused a statistically significant effect within but not between labs. The between-study
437 variance in lab’s true effect size was negligible ($\hat{\tau}^2 = 0.003$) and not statistically significant
438 ($\chi^2(2) = 0.355$, p -value = 0.837). The correlation between the intercepts and slopes of the
439 labs was equal to 0.371.

440 Figure 2 provides an overview of the effect of (mean) age within and between labs. The
441 solid line represents the relationship between labs that was estimated by the meta-regression
442 model. Squares denote the observed effect size and mean age per lab with the dashed line
443 reflecting the effect of age within each lab that was obtained in the first step of the two-stage
444 IPD meta-analysis. The slope of a dashed line illustrates to what extent the treatment effect
445 within a lab is moderated by age. Although the slopes of the within lab effect differs across
446 labs, this figure corroborates the results in Table 3 showing that the effect of (mean) age was
447 not substantially different between and within labs.




Figure 2. This figure shows the effect of participant's age and mean age per lab on the raw mean difference in the RRR by McCarthy et al. (2018). Squares denote the observed effect sizes and mean age in the labs. The size of a squares is proportional to the inverse of the standard error of the effect sizes. The solid line shows the estimated effect between labs based on the meta-regression. The dashed lines show the effect of age within lab obtained in the two-stage IPD meta-analysis (i.e., $\hat{\gamma}_i$ in model (3)). The length of the dashed lines is proportional to the standard deviation of age per lab.

Conclusion

448

449 Multilab replication projects are becoming more popular to examine whether an effect
450 can be replicated and to what extent it depends on contextual factors. Data of these projects
451 are commonly analyzed using lab's summary statistics by means of conventional
452 meta-analysis methods. This is certainly a suboptimal approach, because differences within a
453 lab are lost. This paper illustrated a better approach for analyzing data of multilab
454 replication projects using IPD meta-analysis.

455 IPD meta-analysis allows for distinguishing the effect at the participant and lab level
456 in contrast to conventional meta-analysis models. An artificial example illustrated that
457 drawing conclusions at the participant level using the conventional meta-regression model is
458 not allowed, and that it could lead to committing an ecological fallacy if it is done. Other
459 advantages of IPD meta-analysis are larger statistical power for testing moderator effects
460 than conventional meta-analysis (Lambert, Sutton, Abrams, & Jones, 2002; Simmonds &
461 Higgins, 2007) and more modeling flexibility. Applying one-stage and two-stage IPD
462 meta-analysis to the RRR by McCarthy et al. (2018) did not alter the main conclusion that
463 assimilative priming had a small but statistically significant effect on hostility ratings. An
464 interesting finding obtained with IPD meta-analysis was that the moderating effect of age
465 was present within but not between labs.

466 IPD meta-analysis was illustrated by using raw mean difference as effect size measure,
467 because this is a common effect size measure for multilab replication projects and it was used
468 in the RRR of McCarthy et al. (2018). However, these models can also be applied for other
469 effect size measures as, for example, the correlation coefficient and binary data (see for
470 illustrations Pigott, Williams, & Polanin, 2012; Turner, Omar, Yang, Goldstein, &
471 Thompson, 2000; Whitehead, 2002). In case of the Pearson correlation coefficient, the
472 independent and dependent variable need to be standardized before being included in a
473 one-stage IPD meta-analysis. The one-stage IPD meta-analysis then returns an estimate of

474 the average correlation, because the regression coefficient of a standardized dependent
475 variable regressed on a standardized independent variable equals a Pearson correlation
476 coefficient. An IPD meta-analysis based on binary data is generally less cumbersome than
477 for other effect size measures since participant data can be extracted from cell frequencies of
478 contingency tables in a study.

479 I recommend to analyze data of any multilab replication project using one-stage IPD
480 meta-analysis. One-stage IPD meta-analysis is preferred over two-stage IPD meta-analysis,
481 because it generally has larger statistical power (Fisher, Copas, Tierney, & Parmar, 2011;
482 Simmonds & Higgins, 2007) and has more modeling flexibility. For example, moderators at
483 the first level (participant) and second level (lab) can be added as well as interaction effects
484 between these moderators or an extra random effect can be added to take into account that
485 labs are located in different countries. The model flexibility of a one-stage IPD meta-analysis
486 can also be used to make different assumptions about the within-study residual variance.
487 This residual variance was assumed to be the same in all control and experimental groups of
488 the labs in the used one-stage IPD meta-analysis, but researchers may have theoretical
489 reasons to impose a weaker assumption on the within-study residual variance. Another
490 advantage of one-stage IPD meta-analysis is that it does not require specialized meta-analysis
491 software in contrast to two-stage IPD meta-analysis and also conventional meta-analysis.
492 Popular statistical software packages such as R, SPSS, Stata, and SAS all include
493 functionality to fit multilevel models that can also be used for one-stage IPD meta-analysis.

494 A drawback of one-stage IPD meta-analysis is that it is more complex to implement
495 compared to two-stage IPD and conventional meta-analysis. This increased complexity is
496 caused by the modeling flexibility that requires researchers to carefully think about how to
497 specify their model. This complexity of one-stage IPD meta-analysis is illustrated by
498 Jackson, Law, Stijnen, Viechtbauer, and White (2018) who identified six one-stage IPD
499 meta-analysis models for synthesizing studies with odds ratio as effect size measure and five

500 of these models showed acceptable statistical properties. Hence, there is currently not a
501 single one-stage IPD meta-analysis model, and future research is needed to assess what the
502 best one-stage IPD meta-analysis models are. Another drawback of one-stage IPD
503 meta-analysis is that convergence problems may arise. These problems may be solved by
504 simplifying the random part of the model. For example, researchers may opt for one-stage
505 IPD meta-analysis with fixed rather than random lab effects. Researchers may use two-stage
506 IPD meta-analysis to analyze their data as a last resort if convergence problems of one-stage
507 IPD meta-analysis cannot be resolved.

508 This paper and the proposed recommendations are in line with a recent paper
509 (McShane & Böckenholt, 2020) that advocated meta-analysts by means of a thought
510 experiment to think about how they would analyze their data if they would possess the
511 participant data rather than only the summary data. This thought experiment will motivate
512 researchers to apply more advanced and appropriate meta-analysis models such as a
513 three-level meta-analysis model (e.g., Konstantopoulos, 2011; Noortgate & Onghena, 2003)
514 when the nesting of studies in labs is, for instance, taken into account or multivariate
515 meta-analysis where multiple outcomes are analyzed simultaneously (e.g., Hedges, 2019; Van
516 Houwelingen, Arends, & Stijnen, 2002). One-stage IPD meta-analysis is also ideally suited
517 for fitting these more advanced meta-analysis models due to its modeling flexibility if the
518 participant data are available.

519 Fitting IPD meta-analysis models to data in psychology and this tutorial paper in
520 particular may become more relevant in the distant future when publishing participant data
521 hopefully becomes the norm. However, IPD meta-analysis models can already be applied
522 within psychology in other situations than multilab replication projects. For instance,
523 meta-analyzing studies in a multistudy paper in a so-called internal meta-analysis (e.g.,
524 Cumming, 2008, 2012; Maner, 2014; McShane & Böckenholt, 2017) has increased in
525 popularity (Ueno, Fastrich, & Murayama, 2016). The usual approach of an internal

526 meta-analysis is to meta-analyze summary data whereas analyzing the participant data by
527 means of an IPD meta-analysis is a better alternative. There are, however, also rare cases
528 where computing summary statistics based on IPD data is beneficial. In case of Big Data, it
529 may be unfeasible to analyze the IPD data directly, because the data are too large to handle
530 with a computer. A solution could be to analyze the data using a
531 split/analyze/meta-analyze (SAM) approach where the data are (1) split into smaller chunks,
532 (2) each chunk is analyzed separately, and (3) the results of the analysis of each chunk are
533 combined using a meta-analysis (Cheung & Jak, 2016; Zhang, Liu, Xu, Yang, & Zhang,
534 2018). This approach is comparable to two-stage IPD meta-analysis.

535 To conclude, application of IPD meta-analysis methods to multilab replication projects
536 has the potential to yield relevant insights that could not have been obtained by
537 conventional meta-analysis methods. I hope that this paper creates awareness for IPD
538 meta-analysis methods within the research field of psychology and enables researchers to
539 apply these methods to their own data.

540 **Funding:**

541 This work was supported by the European Research Council. Grant Number: 726361
542 (IMPROVE).

543 **Disclosure statement:**

544 The author declare that there were no conflicts of interest with respect to the
545 authorship or the publication of this article.

546 **Data Availability Statement:**

547 The data sets analyzed in this paper are available on the Open Science Framework on
548 the project page of McCarthy et al. (2018), <https://osf.io/qegfd/>.

549 **Supplemental online material:**

550 Annotated R code used to analyze the data is available in the supplemental materials
551 at <https://osf.io/c9zep/>. Details about the Monte-Carlo simulation study, R code, and all
552 results are available in the supplemental materials at <https://osf.io/r5kqy/>.

References

- 553
- 554 Aitkin, M., & Longford, N. (1986). Statistical modelling issues in school effectiveness
555 studies. *Journal of the Royal Statistical Society. Series A (General)*, *149*(1), 1–43.
- 556 Aust, F., & Barth, M. (2020). papaja: Prepare reproducible APA journal articles
557 with R Markdown. Retrieved from <https://github.com/crsh/papaja>
- 558 Baguley, T. (2009). Standardized or simple effect size: What should be reported?
559 *British Journal of Psychology*, *100*(3), 603–617.
560 <https://doi.org/10.1348/000712608X377117>
- 561 Bates, D., Mächler, M., Bolker, B., & Walker, S. (2015). Fitting linear mixed-effects
562 models using lme4. *Journal of Statistical Software*, *67*(1), 48.
563 <https://doi.org/10.18637/jss.v067.i01>
- 564 Berlin, J. A., Santanna, J., Schmid, C. H., Szczech, L. A., & Feldman, H. I. (2002).
565 Individual patient- versus group-level data meta-regressions for the investigation
566 of treatment effect modifiers: Ecological bias rears its ugly head. *Statistics in*
567 *Medicine*, *21*(3), 371–387. <https://doi.org/10.1002/sim.1023>
- 568 Bond Jr., C. F., Wiitala, W. L., & Richard, F. D. (2003). Meta-analysis of raw mean
569 differences. *Psychological Methods*, *8*(4), 406–418.
570 <https://doi.org/10.1037/1082-989X.8.4.406>
- 571 Borenstein, M., & Hedges, L. V. (2019). Effect sizes for meta-analysis. In H. Cooper,
572 L. V. Hedges, & J. C. Valentine (Eds.), *The handbook of research synthesis and*
573 *meta-analysis* (3rd ed., pp. 207–244). New York: Rusell Sage Foundation.
- 574 Borenstein, M., Hedges, L. V., Higgins, J. P. T., & Rothstein, H. R. (2009).
575 *Introduction to meta-analysis*. Chichester, UK: John Wiley & Sons, Ltd.

- 576 Brown, H., & Prescott, R. (2015). *Applied mixed models in medicine*. Chichester,
577 West Sussex: John Wiley & Sons, Ltd.
- 578 Cheung, M. W.-L., & Jak, S. (2016). Analyzing big data in psychology: A
579 split/analyze/meta-analyze approach. *Frontiers in Psychology*, 7(738).
580 <https://doi.org/10.3389/fpsyg.2016.00738>
- 581 Chung, Y., Rabe-Hesketh, S., Dorie, V., Gelman, A., & Liu, J. (2013). A
582 nondegenerate penalized likelihood estimator for variance parameters in multilevel
583 models. *Psychometrika*, 78(4), 685–709.
584 <https://doi.org/10.1007/s11336-013-9328-2>
- 585 Cochran, W. G. (1954). The combination of estimates from different experiments.
586 *Biometrics*, 10(1), 101–129.
- 587 Cumming, G. (2008). Replication and p intervals: p values predict the future only
588 vaguely, but confidence intervals do much better. *Perspectives on Psychological
589 Science*, 3(4), 286–300. <https://doi.org/10.1111/j.1745-6924.2008.00079.x>
- 590 Cumming, G. (2012). *Understanding the new statistics: Effect sizes, confidence
591 intervals, and meta-analysis*. New York: Routledge.
- 592 Ebersole, C. R., Atherton, O. E., Belanger, A. L., Skulborstad, H. M., Allen, J. M.,
593 Banks, J. B., ... Nosek, B. A. (2016). Many Labs 3: Evaluating participant pool
594 quality across the academic semester via replication. *Journal of Experimental
595 Social Psychology*, 67, 68–82. <https://doi.org/10.1016/j.jesp.2015.10.012>
- 596 Ebersole, C. R., Mathur, M. B., Baranski, E., Bart-Plange, D.-J., Buttrick, N. R.,
597 Chartier, C. R., ... Nosek, B. A. (2020). Many Labs 5: Testing
598 pre-data-collection peer review as an intervention to increase replicability.
599 *Advances in Methods and Practices in Psychological Science*, 3(3), 309–331.

600 <https://doi.org/10.1177/2515245920958687>

601 Enders, C. K., & Tofghi, D. (2007). Centering predictor variables in cross-sectional
602 multilevel models: A new look at an old issue. *Psychological Methods, 12*(2),
603 121–138. <https://doi.org/10.1037/1082-989X.12.2.121>

604 Fisher, D. J., Copas, A. J., Tierney, J. F., & Parmar, M. K. B. (2011). A critical
605 review of methods for the assessment of patient-level interactions in individual
606 participant data meta-analysis of randomized trials, and guidance for
607 practitioners. *Journal of Clinical Epidemiology, 64*(9), 949–967.
608 <https://doi.org/10.1016/j.jclinepi.2010.11.016>

609 Godlee, F. (2012). Clinical trial data for all drugs in current use. *BMJ, 345*, e7304.
610 <https://doi.org/10.1136/bmj.e7304>

611 Hedges, L. V. (2019). Stochastically dependent effect sizes. In H. Cooper, L. V.
612 Hedges, & J. C. Valentine (Eds.), *The handbook of research synthesis and*
613 *meta-analysis* (3rd ed., pp. 281–297). New York: Russell Sage Foundation.

614 Higgins, J. P. T., Whitehead, A., Turner, R. M., Omar, R. Z., & Thompson, S. G.
615 (2001). Meta-analysis of continuous outcome data from individual patients.
616 *Statistics in Medicine, 20*(15), 2219–2241. <https://doi.org/10.1002/sim.918>

617 Hingorani, A. D., Windt, D. A. van der, Riley, R. D., Abrams, K. R., Moons, K. G.
618 M., Steyerberg, E. W., . . . Hemingway, H. (2013). Prognosis research strategy
619 (PROGRESS) 4: Stratified medicine research. *BMJ, 346*, e5793.
620 <https://doi.org/10.1136/bmj.e5793>

621 Hox, J. J., Moerbeek, M., & Van de Schoot, R. (2018). *Multilevel analysis:*
622 *Techniques and applications*. New York: Routledge.

623 Jackson, D., Law, M., Stijnen, T., Viechtbauer, W., & White, I. R. (2018). A
624 comparison of 7 random-effects models for meta-analyses that estimate the
625 summary odds ratio. *Statistics in Medicine*, *37*, 1059–1085.
626 <https://doi.org/10.1002/sim.7588>

627 Klein, R. A., Cook, C. L., Ebersole, C. R., Vitiello, C. A., Nosek, B. A., Chartier, C.
628 R., . . . Ratliff, K. A. (2021). Many Labs 4: Failure to replicate mortality salience
629 effect with and without original author involvement.
630 <https://doi.org/10.31234/osf.io/vef2c>

631 Klein, R. A., Ratliff, K. A., Vianello, M., Adams Jr, R. B., Bahník, Š., Bernstein, M.
632 J., . . . Nosek, B. A. (2014). Investigating variation in replicability: A “many labs”
633 replication project. *Social Psychology*, *45*(3), 142–152.
634 <https://doi.org/10.1027/1864-9335/a000178>

635 Klein, R. A., Vianello, M., Hasselman, F., Adams, B. G., Adams, R. B., Alper, S., . . .
636 Nosek, B. A. (2018). Many Labs 2: Investigating variation in replicability across
637 samples and settings. *Advances in Methods and Practices in Psychological Science*,
638 *1*(4), 443–490. <https://doi.org/10.1177/2515245918810225>

639 Konstantopoulos, S. (2011). Fixed effects and variance components estimation in
640 three-level meta-analysis. *Research Synthesis Methods*, *2*(1), 61–76.
641 <https://doi.org/10.1002/jrsm.35>

642 Kontopantelis, E. (2018). A comparison of one-stage vs two-stage individual patient
643 data meta-analysis methods: A simulation study. *Research Synthesis Methods*,
644 *9*(3), 417–430. <https://doi.org/10.1002/jrsm.1303>

645 Koopman, L., Van der Heijden, G. J. M. G., Hoes, A. W., Grobbee, D. E., & Rovers,
646 M. M. (2008). Empirical comparison of subgroup effects in conventional and

- 647 individual patient data meta-analyses. *International Journal of Technology*
648 *Assessment in Health Care*, 24(3), 358–361.
649 <https://doi.org/10.1017/S0266462308080471>
- 650 Kuznetsova, A., Brockhoff, P. B., & Christensen, R. H. B. (2017). lmerTest Package:
651 Tests in Linear Mixed Effects Models. *Journal of Statistical Software*, 82(1), 1–26.
652 <https://doi.org/10.18637/jss.v082.i13>
- 653 Lambert, P. C., Sutton, A. J., Abrams, K. R., & Jones, D. R. (2002). A comparison
654 of summary patient-level covariates in meta-regression with individual patient
655 data meta-analysis. *Journal of Clinical Epidemiology*, 55(1), 86–94.
656 [https://doi.org/10.1016/S0895-4356\(01\)00414-0](https://doi.org/10.1016/S0895-4356(01)00414-0)
- 657 Loder, E., & Groves, T. (2015). The BMJ requires data sharing on request for all
658 trials. *BMJ*, 350, h2373. <https://doi.org/10.1136/bmj.h2373>
- 659 Luke, S. G. (2017). Evaluating significance in linear mixed-effects models in R.
660 *Behavior Research Methods*, 49(4), 1494–1502.
661 <https://doi.org/10.3758/s13428-016-0809-y>
- 662 Maner, J. K. (2014). Let’s put our money where our mouth is: If authors are to
663 change their ways, reviewers (and editors) must change with them. *Perspectives on*
664 *Psychological Science*, 9(3), 343–351. <https://doi.org/10.1177/1745691614528215>
- 665 McCarthy, R. J., Skowronski, J. J., Verschuere, B., Meijer, E. H., Jim, A.,
666 Hoogesteyn, K., ... Yıldız, E. (2018). Registered replication report on Srull and
667 Wyer (1979). *Advances in Methods and Practices in Psychological Science*, 1(3),
668 321–336. <https://doi.org/10.1177/2515245918777487>
- 669 McShane, B. B., & Böckenholt, U. (2017). Single-paper meta-analysis: Benefits for
670 study summary, theory testing, and replicability. *Journal of Consumer Research*,

671 43(6), 1048–1063. <https://doi.org/10.1093/jcr/ucw085>

672 McShane, B. B., & Böckenholt, U. (2020). Enriching meta-analytic models of
673 summary data: A thought experiment and case study. *Advances in Methods and*
674 *Practices in Psychological Science*, 3(1), 81–93.
675 <https://doi.org/10.1177/2515245919884304>

676 Noortgate, W. van den, & Onghena, P. (2003). Multilevel meta-analysis: A
677 comparison with traditional meta-analytical procedures. *Educational and*
678 *Psychological Measurement*, 63(5), 765–790.

679 Olsson-Collentine, A., Wicherts, J. M., & Van Assen, M. A. L. M. (2020).
680 Heterogeneity in direct replications in psychology and its association with effect
681 size. *Psychological Bulletin*, 146(10), 922–940.
682 <https://doi.org/10.1037/bul0000294>

683 Papadimitropoulou, K., Stijnen, T., Dekkers, O. M., & Cessie, S. le. (2019).
684 One-stage random effects meta-analysis using linear mixed models for aggregate
685 continuous outcome data. *Research Synthesis Methods*, 10(3), 360–375.
686 <https://doi.org/10.1002/jrsm.1331>

687 Pigott, T. D., Williams, R., & Polanin, J. (2012). Combining individual participant
688 and aggregated data in a meta-analysis with correlational studies. *Research*
689 *Synthesis Methods*, 3(4), 257–268. <https://doi.org/10.1002/jrsm.1051>

690 R Core Team. (2021). R: A language and environment for statistical computing.
691 Retrieved from <http://www.r-project.org/>

692 Raudenbush, S. W. (2009). Analyzing effect sizes: Random-effects models. In H.
693 Cooper, L. V. Hedges, & J. C. Valentine (Eds.), *The handbook of research*
694 *synthesis and meta-analysis* (pp. 295–315). New York: Russell Sage Foundation.

- 695 Riley, R. D., Lambert, P. C., & Abo-Zaid, G. (2010). Meta-analysis of individual
696 participant data: Rationale, conduct, and reporting. *BMJ*, *340*.
697 <https://doi.org/10.1136/bmj.c221>
- 698 Riley, R. D., Lambert, P. C., Staessen, J. A., Wang, J., Gueyffier, F., Thijs, L., &
699 Boutitie, F. (2008). Meta-analysis of continuous outcomes combining individual
700 patient data and aggregate data. *Statistics in Medicine*, *27*(11), 1870–1893.
701 <https://doi.org/10.1002/sim.3165>
- 702 Robinson, W. S. (1950). Ecological correlations and the behavior of individuals.
703 *American Sociological Review*, *15*(3), 351–357. <https://doi.org/10.2307/2087176>
- 704 Rogozińska, E., Marlin, N., Thangaratinam, S., Khan, K. S., & Zamora, J. (2017).
705 Meta-analysis using individual participant data from randomised trials:
706 Opportunities and limitations created by access to raw data. *Evidence Based
707 Medicine*, *22*(5), 157–162. <https://doi.org/10.1136/ebmed-2017-110775>
- 708 Schmid, C. H., Stark, P. C., Berlin, J. A., Landais, P., & Lau, J. (2004).
709 Meta-regression detected associations between heterogeneous treatment effects
710 and study-level, but not patient-level, factors. *Journal of Clinical Epidemiology*,
711 *57*(7), 683–697. <https://doi.org/10.1016/j.jclinepi.2003.12.001>
- 712 Simmonds, M. C., & Higgins, J. P. T. (2007). Covariate heterogeneity in
713 meta-analysis: Criteria for deciding between meta-regression and individual
714 patient data. *Statistics in Medicine*, *26*(15), 2982–2999.
715 <https://doi.org/10.1002/sim.2768>
- 716 Simmonds, M. C., Higgins, J. P. T., Stewart, L. A., Tierney, J. F., Clarke, M. J., &
717 Thompson, S. G. (2005). Meta-analysis of individual patient data from
718 randomized trials: A review of methods used in practice. *Clinical Trials*, *2*(3),

719 209–217. <https://doi.org/10.1191/1740774505cn087oa>

720 Simons, D. J., Holcombe, A. O., & Spellman, B. A. (2014). An introduction to
721 registered replication reports at Perspectives on Psychological Science.
722 *Perspectives on Psychological Science*, 9(5), 552–555.
723 <https://doi.org/10.1177/1745691614543974>

724 Snijders, T. A. B., & Bosker, R. J. (1999). *Multilevel analysis: An introduction to*
725 *basic and advanced multilevel modeling*. London; Thousand Oaks: Sage
726 Publications.

727 Srull, T. K., & Wyer, R. S. (1979). The role of category accessibility in the
728 interpretation of information about persons: Some determinants and implications.
729 *Journal of Personality and Social Psychology*, 37(10), 1660–1672.
730 <https://doi.org/10.1037/0022-3514.37.10.1660>

731 Stewart, G. B., Altman, D. G., Askie, L. M., Duley, L., Simmonds, M. C., & Stewart,
732 L. A. (2012). Statistical analysis of individual participant data meta-analyses: A
733 comparison of methods and recommendations for practice. *PLOS ONE*, 7(10),
734 e46042. <https://doi.org/10.1371/journal.pone.0046042>

735 Stewart, L. A., & Tierney, J. F. (2002). To IPD or not to IPD? Advantages and
736 disadvantages of systematic reviews using individual patient data. *Evaluation &*
737 *the Health Professions*, 25(1), 76–97.
738 <https://doi.org/10.1177/0163278702025001006>

739 Thompson, S. G., & Sharp, S. J. (1999). Explaining heterogeneity in meta-analysis:
740 A comparison of methods. *Statistics in Medicine*, 18(20), 2693–2708.
741 [https://doi.org/10.1002/\(SICI\)1097-0258\(19991030\)18:20%3C2693::AID-](https://doi.org/10.1002/(SICI)1097-0258(19991030)18:20%3C2693::AID-SIM235%3E3.0.CO;2-V)
742 [SIM235%3E3.0.CO;2-V](https://doi.org/10.1002/(SICI)1097-0258(19991030)18:20%3C2693::AID-SIM235%3E3.0.CO;2-V)

- 743 Tierney, J. F., Fisher, D. J., Burdett, S., Stewart, L. A., & Parmar, M. K. B. (2020).
744 Comparison of aggregate and individual participant data approaches to
745 meta-analysis of randomised trials: An observational study. *PLOS Medicine*,
746 *17*(1), e1003019. <https://doi.org/10.1371/journal.pmed.1003019>
- 747 Tudur Smith, C., Marcucci, M., Nolan, S. J., Iorio, A., Sudell, M., Riley, R., . . .
748 Williamson, P. R. (2016). Individual participant data meta-analyses compared
749 with meta-analyses based on aggregate data. *Cochrane Database of Systematic*
750 *Reviews*, (9). <https://doi.org/10.1002/14651858.MR000007.pub3>
- 751 Tudur Smith, C., & Williamson, P. R. (2007). A comparison of methods for fixed
752 effects meta-analysis of individual patient data with time to event outcomes.
753 *Clinical Trials*, *4*(6), 621–630. <https://doi.org/10.1177/1740774507085276>
- 754 Turner, R. M., Omar, R. Z., Yang, M., Goldstein, H., & Thompson, S. G. (2000). A
755 multilevel model framework for meta-analysis of clinical trials with binary
756 outcomes. *Statistics in Medicine*, *19*(24), 3417–3432.
- 757 Ueno, T., Fastrich, G. M., & Murayama, K. (2016). Meta-analysis to integrate effect
758 sizes within an article: Possible misuse and Type I error inflation. *Journal of*
759 *Experimental Psychology: General*, *145*(5), 643–654.
760 <https://doi.org/10.1037/xge0000159>
- 761 Van Houwelingen, H. C., Arends, L. R., & Stijnen, T. (2002). Advanced methods in
762 meta-analysis: Multivariate approach and meta-regression. *Statistics in Medicine*,
763 *21*(4), 589–624. <https://doi.org/10.1002/sim.1040>
- 764 Viechtbauer, W. (2007). Confidence intervals for the amount of heterogeneity in
765 meta-analysis. *Statistics in Medicine*, *26*(1), 37–52.
766 <https://doi.org/10.1002/sim.2514>

- 767 Viechtbauer, W. (2010). Conducting meta-analyses in R with the metafor package.
768 *Journal of Statistical Software*, *36*(3), 1–48. <https://doi.org/10.18637/jss.v036.i03>
- 769 Whitehead, A. (2002). *Meta-analysis of controlled clinical trials*. Chichester: John
770 Wiley.
- 771 Wilkinson, L. (1999). Statistical methods in psychology journals: Guidelines and
772 explanations. *American Psychologist*, *54*(8), 594–604.
773 <https://doi.org/10.1037/0003-066X.54.8.594>
- 774 Zhang, Y. E., Liu, S., Xu, S., Yang, M. M., & Zhang, J. (2018). Integrating the
775 split/analyze/meta-analyze (SAM) approach and a multilevel framework to
776 advance big data research in psychology: Guidelines and an empirical illustration
777 via the human Resource management investment-firm performance relationship.
778 *Zeitschrift für Psychologie*, *226*(4), 274–283.
779 <https://doi.org/10.1027/2151-2604/a000345>